PFE | Weekly | Haru Insights

Pfizer received FDA approval for its updated COMIRNATY XFG-adapted mRNA vaccine for the 2026–2027 season, reinforcing its leadership in mRNA technology and public health readiness.
The European Medicines Agency (EMA) validated Pfizer’s Lyme disease vaccine candidate, PF-07307405, marking a major strategic milestone and potential first-ever Lyme vaccine in Europe and North America.

Pfizer’s FDA-approved XFG-adapted COMIRNATY vaccine reaffirms its enduring leadership in mRNA innovation, delivering a stable, high-margin revenue stream amid post-pandemic normalization and solidifying its role as a public health cornerstone.
The EMA validation of the Lyme disease vaccine candidate signals a transformative leap beyond pandemic-era assets, validating Pfizer’s next-generation preventive biologics platform and expanding its infectious disease footprint into a high-unmet-need market.
The successful FDA approval of Lisraya (brepocitinib) for dermatomyositis—developed via a Pfizer-backed biotech partnership—cements pipeline credibility, demonstrating outsized value from its venture investing strategy and de-risking future innovation.
Pfizer’s aggressive pivot into the GLP-1 weight-loss market via a strategic acquisition positions it as a credible challenger in a high-growth sector, potentially unlocking a new blockbuster franchise with strong commercial scalability.
Despite macro headwinds, Pfizer continues to deliver above-consensus revenue performance nine out of the last ten quarters, showcasing unmatched execution discipline in a turbulent industry and underscoring operational resilience.

Pfizer Inc. (PFE)[Tv]